JO3170B1 - مركبات و تراكيب لتثبيت parp و طرق استعمالها - Google Patents

مركبات و تراكيب لتثبيت parp و طرق استعمالها

Info

Publication number
JO3170B1
JO3170B1 JOP/2008/0433A JOP20080433A JO3170B1 JO 3170 B1 JO3170 B1 JO 3170B1 JO P20080433 A JOP20080433 A JO P20080433A JO 3170 B1 JO3170 B1 JO 3170B1
Authority
JO
Jordan
Prior art keywords
inhibitor compounds
relates
parp inhibitor
compounds
disclosed
Prior art date
Application number
JOP/2008/0433A
Other languages
English (en)
Inventor
Zhang Jie
Delahanty Greg
Wei Ling
Xu Weizheng
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3170(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of JO3170B1 publication Critical patent/JO3170B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الراهن بمركبات رابع ازاز فنالين -3- ون تثبط انزيم بولي( ADP- ribose) بوليميراز ( PARP) وهي مفيدة في ا لاحساس الكيميائي لعقاقير علاج السرطان، يعتبر حث المرض العصبي المحيطي من التاثيرات الجانبية الشائعه في العددي من عقاقير العلاج الكيميائي التقليدية والجديدة، والاختراع الراهن يكفل وسائل لمنع او علاج المرض العصبي المحفز بالعلاج الكيميائي بكفاءه، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في تعزيز كفاءه عوامل العلاج الكيميائي مثل تيموزواوميد، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في الخلايا الحساسة للاشعاع وذلك لتاين الاشعاع، ويتعلق الاختراع كذلك باستعمال مركبات تثبيط PARP موضوع الاختراع في علاج السرطان الذي يتميز بعيوب اصلاح DNA .
JOP/2008/0433A 2007-10-03 2008-10-05 مركبات و تراكيب لتثبيت parp و طرق استعمالها JO3170B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97711507P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
JO3170B1 true JO3170B1 (ar) 2017-09-20

Family

ID=40526672

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2008/0433A JO3170B1 (ar) 2007-10-03 2008-10-05 مركبات و تراكيب لتثبيت parp و طرق استعمالها

Country Status (28)

Country Link
US (3) US8236802B2 (ar)
EP (2) EP2842956A1 (ar)
JP (1) JP5439380B2 (ar)
KR (1) KR101596526B1 (ar)
CN (1) CN102083314B (ar)
AU (1) AU2008308664B2 (ar)
BR (1) BRPI0820518B1 (ar)
CA (1) CA2700903C (ar)
CL (1) CL2010000320A1 (ar)
CY (1) CY1115747T1 (ar)
DK (1) DK2209375T3 (ar)
ES (1) ES2504690T3 (ar)
HK (1) HK1146792A1 (ar)
HR (1) HRP20140853T1 (ar)
IL (1) IL204776A (ar)
JO (1) JO3170B1 (ar)
MX (1) MX2010003564A (ar)
MY (1) MY155237A (ar)
NZ (1) NZ585012A (ar)
PL (1) PL2209375T3 (ar)
PT (1) PT2209375E (ar)
RU (1) RU2485122C2 (ar)
SG (1) SG185272A1 (ar)
SI (1) SI2209375T1 (ar)
TW (1) TWI426912B (ar)
UA (1) UA99483C2 (ar)
WO (1) WO2009046205A1 (ar)
ZA (1) ZA201002317B (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206512B2 (en) 2005-01-19 2012-09-13 Eisai Inc. Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
KR101846029B1 (ko) * 2008-08-06 2018-04-06 메디베이션 테크놀로지즈 엘엘씨 폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
EP2533640B1 (en) * 2010-02-08 2016-09-28 Medivation Technologies, Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
ES2609931T3 (es) 2010-06-18 2017-04-25 Myriad Genetics, Inc. Métodos y materiales para evaluar la pérdida de heterocigosidad
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2012122645A1 (en) * 2011-03-11 2012-09-20 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
CA2832817A1 (en) * 2011-04-11 2012-10-18 Abbvie Inc. Parp inhibitors for the treatment of cipn
CA2835339A1 (en) 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of cancer aggressiveness and genetic instability
JP2014520858A (ja) * 2011-07-13 2014-08-25 ノバルティス アーゲー タンキラーゼ阻害剤として用いるための新規な２−ピペリジン−１−イル−アセトアミド化合物
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
FI2794907T4 (fi) * 2011-12-21 2023-03-27 Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN104945406B (zh) * 2015-05-25 2017-10-10 苏州康润医药有限公司 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用
CA2993270C (en) 2015-07-23 2019-07-16 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021249996A1 (en) 2020-06-08 2021-12-16 Oncology Venture ApS Compositions comprising 2x-121 and methods for treating coronavirus infection
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US5950784A (en) 1997-09-03 1999-09-14 Yang; Shu-Chiung C. Hub structural improvement
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
MXPA05009661A (es) * 2003-03-12 2006-03-08 Kudos Pharm Ltd Derivados de ftalazinona.
MXPA05012812A (es) * 2003-05-28 2006-02-28 Guilford Pharm Inc Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
MXPA05013145A (es) * 2003-06-10 2006-03-17 Hoffmann La Roche Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno.
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
EP1786850B1 (en) 2004-08-04 2008-11-26 Phosphonics LTD Substituted organopolysiloxanes and use thereof
AU2006206512B2 (en) 2005-01-19 2012-09-13 Eisai Inc. Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
US7981887B2 (en) 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
CN103097355A (zh) 2010-07-08 2013-05-08 惠氏有限责任公司 用于治疗皮肤病的新的喹啉酯

Also Published As

Publication number Publication date
MX2010003564A (es) 2010-09-10
JP5439380B2 (ja) 2014-03-12
AU2008308664B2 (en) 2014-07-17
IL204776A (en) 2015-09-24
IL204776A0 (en) 2010-11-30
CN102083314A (zh) 2011-06-01
RU2010117397A (ru) 2011-11-10
CY1115747T1 (el) 2017-01-25
WO2009046205A1 (en) 2009-04-09
EP2209375A1 (en) 2010-07-28
PL2209375T3 (pl) 2014-12-31
US8236802B2 (en) 2012-08-07
MY155237A (en) 2015-09-30
CA2700903C (en) 2017-05-30
RU2485122C2 (ru) 2013-06-20
CL2010000320A1 (es) 2011-03-11
EP2842956A1 (en) 2015-03-04
NZ585012A (en) 2012-06-29
CN102083314B (zh) 2014-04-30
BRPI0820518A2 (pt) 2020-01-14
BRPI0820518B1 (pt) 2021-09-28
US20090098084A1 (en) 2009-04-16
TWI426912B (zh) 2014-02-21
UA99483C2 (ru) 2012-08-27
TW200932239A (en) 2009-08-01
HK1146792A1 (en) 2011-07-15
PT2209375E (pt) 2014-10-08
ZA201002317B (en) 2013-09-25
US20150141429A1 (en) 2015-05-21
SG185272A1 (en) 2012-11-29
EP2209375A4 (en) 2011-03-09
JP2010540655A (ja) 2010-12-24
SI2209375T1 (sl) 2014-12-31
KR20100100771A (ko) 2010-09-15
ES2504690T3 (es) 2014-10-08
KR101596526B1 (ko) 2016-02-22
CA2700903A1 (en) 2009-04-09
HRP20140853T1 (hr) 2014-10-24
DK2209375T3 (da) 2014-10-06
EP2209375B1 (en) 2014-08-27
US20130011365A1 (en) 2013-01-10
AU2008308664A1 (en) 2009-04-09
US8894989B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
JO3170B1 (ar) مركبات و تراكيب لتثبيت parp و طرق استعمالها
IL258880A (en) Compounds of diarylhydantoin
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
SG164368A1 (en) Treatment of cancer
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
IN2012DN01964A (ar)
PE20070496A1 (es) Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
CR10450A (es) Metodo para inhibir la cinasa del c-kit
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
WO2008033887A3 (en) Methods for treating cancer
WO2007050564A3 (en) Boron-containing porphyrin compounds and their uses
Du et al. Expression of Y-box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo
EA201800552A1 (ru) Способ и комбинация для лечения солидной опухоли и набор, содержащий комбинацию
MX2009004437A (es) El uso de un inhibidor de cinasa de multiples objetivos para el tratamiento o la prevencion del cancer cerebral.
TW200503798A (en) Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy